Treatment of overactive bladder in the aging population: focus on darifenacin

References

• AbramsPCardozoLFallM2002The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence SocietyNeurourol Urodyn211677811857671
   PubMed Web of Science ®Google Scholar
• AbramsPKelleherCJKerrLA2000Overactive bladder significantly affects quality of lifeAm J Manag Care6S5809011183901
   PubMed Web of Science ®Google Scholar
• AndersonKE2006Potential benefits of Muscarinic M3 receptor sensitivityEur Urol1Suppl 2002238
   Google Scholar
• BeaumontKCCussansNJNicholsDJ1998Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and manXenobiotica2863759493320
   PubMed Web of Science ®Google Scholar
• BravermanASLuthinGRRuggieriMR1998M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladderAm J Physiol275R1654609791087
   PubMed Web of Science ®Google Scholar
• CardozoLDixonA2005Increased warning time with darifenacin: a new concept in the management of urinary urgencyJ Urol17312141815758755
   PubMed Web of Science ®Google Scholar
• CastledenCMDuffinHMAsherMJ1981Clinical and urodynamic studies in 100 elderly incontinent patientsBr Med J (Clin Res Ed)28211035
   PubMed Web of Science ®Google Scholar
• CaulfieldMPBirdsallNJ1998International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptorsPharmacol Rev50279909647869
   PubMed Web of Science ®Google Scholar
• ChalifouxP1980Urinary continence/incontinence. Recognizing warning time: a critical step toward continenceGeriatr Nurs1254556903539
   PubMedGoogle Scholar
• ChappleCSteersWNortonP2005A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderBJU Int95993100115839920
   PubMed Web of Science ®Google Scholar
• ChappleCKelleherCPerraultL2006Quality of life effects of darifenacin, an M3 selective receptor antagonist, in patients with overactive bladder [Abstract 1136]BJU Int94126
   Google Scholar
• CroomKFKeatingGM2004Darifenacin: in the treatment of overactive bladderDrugs Aging218859215493952
   PubMed Web of Science ®Google Scholar
• FooteJGlavindKKralidisG2005Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonistEur Urol484717715990219
   PubMed Web of Science ®Google Scholar
• FooteJGlavindKKayG2006Central nervous system (CNS)-related adverse events in patients with overactive bladder (OAB) treated with darifenacin versus tolterodine [Abstract 1134]BJU Int9494
   Google Scholar
• GuptaPAndersonCCarterA2006In vivo bladder selectivity of darifenacin, a new M3 antimuscarinic agent, in the anaesthetised dogEur Urol1Suppl. 1131
   Google Scholar
• HaabFStewartLDwyerP2004Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladderEur Urol454202915041104
   PubMed Web of Science ®Google Scholar
• HaabF2005Darifenacin in the treatment of overactive bladderDrugs Today (Barc)414415216193097
   PubMed Web of Science ®Google Scholar
• HarrissDRMarshKABirminghamAT1995Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cellsJ Urol1541241457637095
   PubMed Web of Science ®Google Scholar
• KayGCrookTRekedaL2006Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjectsEur Urol503172616687205
   PubMed Web of Science ®Google Scholar
• KelleherCJCardozoLDKhullarV1997A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBr J Obstet Gynaecol104988939307522
   PubMedGoogle Scholar
• KerbuschTMilliganPAKarlssonMO2004Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataBr J Clin Pharmacol571708014748816
   PubMed Web of Science ®Google Scholar
• KerbuschTWahlbyUMilliganPA2003Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailabilityBr J Clin Pharmacol566395214616424
   PubMed Web of Science ®Google Scholar
• KirwinJL2006Darifenacin: An M3 selective muscarinic antagonist for the treatment of overactive bladderFormulary3929199
   Google Scholar
• MilsomIAbramsPCardozoL2001How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence studyBJU Int877606611412210
   PubMed Web of Science ®Google Scholar
• NapierCGuptaP2002Darifenacin is selective for the human recombinant M3 receptor subtype [Abstract 445]Proceedings of the 32nd Annual meeting of the International Continence Society28–30 AugHeidelberg, Germany
   Google Scholar
• NicholsDColliEGokaJ2006Darifenacin demonstrated no adverse effect on cognitive and cardiac function: results from a double-blind, randomised, placebo-controlled study [abstract]Neurourol Urodyn20354
   Google Scholar
• NicholsDJ2006No effect of food on pharmacokinetics darifenacin in multiple doses. pharmacolToxicol Suppl189
   Google Scholar
• PaineMFKhalighiMFisherJM1997Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolismJ Pharmacol Exp Ther2831552629400033
   PubMed Web of Science ®Google Scholar
• QuinnPMcIntyrePMinerWDWallisRM2006In vivo profile of darifenacin, a selective muscarinic M3 receptor antagonistBr J Clin Pharmacol119198P
   Google Scholar
• RabinJMMcNettJBadlaniGH1993Computerized voiding diaryNeurourol Urodyn12541538312939
   PubMed Web of Science ®Google Scholar
• SchneiderTHeinPMichel-ReherMB2005Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladderNaunyn Schmiedebergs Arch Pharmacol37271816059734
   PubMed Web of Science ®Google Scholar
• SerraDBAffrimeMBBedigianMP2005QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladderJ Clin Pharmacol4510384716100298
   PubMed Web of Science ®Google Scholar
• StaskinDRMacDiarmidSA2006Pharmacologic management of overactive bladder: practical options for the primary care physicianAm J Med11924816483865
   PubMed Web of Science ®Google Scholar
• StaskinDRMacDiarmidSAUsing anticholinergics to treat overactive bladder: the issue of treatment tolerabilityAm J Med11991516483863
   PubMed Web of Science ®Google Scholar
• SteersWCorcosJFooteJ2005An investigation of dose titration with darifenacin, an M3-selective receptor antagonistBJU Int955808615705084
   PubMed Web of Science ®Google Scholar
• StewartWFVan RooyenJBCundiffGW2003Prevalence and burden of overactive bladder in the United StatesWorld J Urol203273612811491
   PubMed Web of Science ®Google Scholar
• TanakaE1999Gender-related differences in pharmacokinetics and their clinical significanceJ Clin Pharm Ther243394610583696
   PubMed Web of Science ®Google Scholar
• WallisRMBurgesRACrossPE2006Darifenacin, a selective muscarinic M3 antagonistPharmacol Res31S54
   Google Scholar
• WilliamsonIJRNewgreenDTNaylorAM2006The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat [abstract]Br J Pharmacol120Suppl
   Google Scholar
• XieHGKimRBWoodAJ2001Molecular basis of ethnic differences in drug disposition and responseAnnu Rev Pharmacol Toxicol418155011264478
   PubMed Web of Science ®Google Scholar
• YamaguchiOShishidoKTamuraK1996Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscleJ Urol1561208138709348
   PubMed Web of Science ®Google Scholar
• ZinnerNTuttleJMarksL2005Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladderWorld J Urol232485216096831
   PubMed Web of Science ®Google Scholar